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Atherosclerosis and Glucose Intolerance in LDLR2/2
Mice – Role of Intestinal Permeability and Macrophage
Activation
Siddhartha S. Ghosh, Jinghua Bie, Jing Wang, Shobha Ghosh*
Department of Internal Medicine, Virginia Commonwealth University Medical Center, Richmond, Virginia, United States of America
Abstract
Association between circulating lipopolysaccharide (LPS) and metabolic diseases (such as Type 2 Diabetes and
atherosclerosis) has shifted the focus from Western diet-induced changes in gut microbiota per se to release of gut
bacteria-derived products into circulation as the possible mechanism for the chronic inflammatory state underlying the
development of these diseases. Under physiological conditions, an intact intestinal barrier prevents this release of LPS
underscoring the importance of examining and modulating the direct effects of Western diet on intestinal barrier function.
In the present study we evaluated two strategies, namely selective gut decontamination and supplementation with oral
curcumin, to modulate Western-diet (WD) induced changes in intestinal barrier function and subsequent development of
glucose intolerance and atherosclerosis. LDLR2/2 mice were fed WD for 16 weeks and either received non-absorbable
antibiotics (Neomycin and polymyxin) in drinking water for selective gut decontamination or gavaged daily with curcumin.
WD significantly increased intestinal permeability as assessed by in vivo translocation of FITC-dextran and plasma LPS levels.
Selective gut decontamination and supplementation with curcumin significantly attenuated the WD-induced increase in
plasma LPS levels (3.32 vs 1.90 or 1.51 EU/ml, respectively) and improved intestinal barrier function at multiple levels
(restoring intestinal alkaline phosphatase activity and expression of tight junction proteins, ZO-1 and Claudin-1).
Consequently, both these interventions significantly reduced WD-induced glucose intolerance and atherosclerosis in
LDLR2/2 mice. Activation of macrophages by low levels of LPS (50 ng/ml) and its exacerbation by fatty acids is likely the
mechanism by which release of trace amounts of LPS into circulation due to disruption of intestinal barrier function induces
the development of these diseases. These studies not only establish the important role of intestinal barrier function, but also
identify oral supplementation with curcumin as a potential therapeutic strategy to improve intestinal barrier function and
prevent the development of metabolic diseases.
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Introduction
Diet-related chronic diseases are the single largest cause of
morbidity and mortality, afflicting.50% of the adult popula-
tion. High fat high cholesterol containing Western diet-
dependent changes in the genetic makeup of human gut
microbiome are thought to underlie this epidemic of chronic
diseases such as obesity, insulin resistance and atherosclerosis.
Although diet-induced changes in gut bacteria per se are
actively researched [1], a role for diet-induced changes of the
gut itself is only beginning to be recognized. Gut microbe
mediated changes in the metabolism of dietary components [2]
and/or intestinal function is likely the underlying mechanism
[3]. Association between circulating bacterial endotoxin lipo-
polysaccharide (LPS) and metabolic diseases has shifted the
focus from actual bacterial infections in the etiology of these
diseases to increased translocation of bacterial products (e.g.,
LPS) due to increase in intestinal permeability [4]. Functionally
altered gut mucosa with increased permeability is seen in
patients with chronic heart failure [5] and although the origin
of chronic inflammation and increased levels of circulating
cytokines in these patients is still unclear, role of small yet
pathological amount of intestinally derived LPS in inducing
systemic inflammation is increasingly being recognized [6].
Furthermore, uremia-induced disruption of colonic epithelial
tight junction proteins and changes in intestinal permeability
results in sustained systemic inflammation associated with
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chronic kidney disease [7] underscoring the importance of
targeted improvement in intestinal barrier function as a
potential therapeutic strategy. While synbiotic therapy has been
shown to decrease bacterial translocation from the gut in a pilot
study [8], attempts to recondition the barrier function through
the use of so called ‘probiotics’, normally applied to the gut,
have lower success in man than animals and are often
incompatible with other pharmacological treatments [9]. For
example, non-steroidal Anti-inflammatory Drugs (NSAIDs)
cause a marked reduction in Lactobacilli and Bifidobacteria,
which act in the maintenance of luminal pH, mucosal
permeability, enterocyte adhesion, mucus production and
immune system modulation, and are often used in probiotic
therapy [10]. Furthermore, probiotic treatment also affects the
metabolism of xenobiotics [11]. Plant-derived substances, or
phytochemicals, e.g. curcumin can potentially offer similar
effects as use of probiotics, although milder and yet free from
these incompatible effects. The present study was undertaken to
evaluate this strategy.
We examined whether ‘‘selective decontamination’’ of the gut
by the use of non-absorbable antibiotics that are active in the
intestinal lumen could attenuate the total release of bacterial
LPS into circulation and thereby reduce chronic inflammation
linked diseases namely Western-diet induced atherosclerosis and
glucose intolerance. The combination of antibiotics used for
standard selective decontamination (neomycin and polymyxin B)
eliminates aerobic Gram-negative bacteria from the mucosal
surfaces of the digestive tract, while the majority of the
anaerobic flora persists and support colonization resistance
[12]. These antibiotics are not absorbed and do not yield
therapeutic serum concentrations in contrast to antibiotics which
induce therapeutic serum concentrations (e.g., ciprofloxacin and
cotrimoxazole) but are ineffective for ‘‘selective decontamina-
tion’’ of the gut [12]. It is hypothesized that by reducing the
total amount of LPS produced within the gut, selective
decontamination will attenuate Western diet-induced increase
in LPS and downstream effect on intestinal barrier function. In
addition we used a phytochemical Curcumin, the principal
component of Curcuma longa, with demonstrated anti-inflam-
matory as well as anti-carcinogenic properties. Pharmacokinetics
of curcumin and its poor systemic bioavailability suggest that it
preferentially targets intestinal epithelial cells [13] and in limited
studies has been shown to improve chemotherapy- [14] or
oxidant-induced [15] intestinal barrier function.
Here we demonstrate that Western diet-induced increase in
intestinal permeability leading to translocation of bacterial
endotoxin LPS is reduced by selective decontamination of the
gut via administration of non-absorbable antibiotics as well as by
oral supplementation with Curcumin resulting in attenuation of
inflammation-linked diseases namely atherosclerosis and glucose
intolerance. This study establishes that targeted improvement of
intestinal barrier function is a viable therapeutic strategy to
attenuate Western diet-induced effects on intestinal mucosa, the
resulting endotoxemia and development of associated diseases.
Material and Methods
All chemicals were obtained from Sigma-Aldrich (St. Louis,
MO) unless indicated otherwise.
Animals, diets and study design
All animal procedures were approved by the Institutional
Animal Care and Use Committees of Virginia Commonwealth
University. LDL receptor knockout mice (LDLR2/2) originally
obtained from Jackson Laboratory and maintained in the
laboratory were used for all studies. Where indicated, at
10 weeks of age mice (littermates) were fed a high fat, high
cholesterol Western type diet (WD, TD88137, Harlan Teklad)
which contained 21% fat, 0.15% cholesterol, and 19.5% casein
by weight with no sodium cholate for 16 weeks. In one set of
studies, non-absorbable antibiotics (100 mg/L Neomycin and
10 mg/L Polymyxin B) were administered in drinking water;
untreated or control mice received normal drinking water. In
second set of studies, Curcumin (100 mg/kg in 0.5% carboxy
methyl cellulose made fresh and administered within 15 min-
utes) was given as daily oral gavage; untreated or control mice
were gavaged with vehicle alone. Administration of antibiotics
or curcumin did not affect the food intake or WD-induced
weight gain (Table 1).
Assessment of Intestinal barrier function
Plasma LPS. Mice were fasted overnight and at the time of
necropsy, blood was collected by cardiac puncture and plasma was
frozen at 280uC until analyzed. Plasma LPS levels were
determined by Endpoint Chromogenic LAL (Lamilus Amebocyte
Lysate) assay (Lonza, Walkersville, Maryland, USA) according to
the manufacturer’s instructions, with the following modifications:
samples were diluted 5–10-fold to avoid interference with
background color and preheated to 70uC for 10 minutes prior to
analyses.
Intestinal alkaline phosphatase activity
measurement. Intestinal alkaline phosphatase activity was
measured as described [16]. Briefly, post-mitochondrial superna-
tant was assayed using p-nitrophenylphosphate as the substrate
and appearance of p-nitrophenol monitored by measuring the
absorbance at 405 nm. Specific enzyme activity was calculated as
nmoles/h/mg protein used.
Translocation of FITC Dextran in vivo. Mice were orally
gavaged with FITC-dextran 4 kDa (600 mg/kg body weight)
dissolved in deionized water and plasma was collected after 4 h.
Using three aliquots of plasma in duplicate, FITC fluorescence
(excitation 488 nm and emission 518 nm) was measured using
Perkin Elmer Victor 3 plate reader and concentration of FITC in
plasma determined using a standard curve and expressed as ng/ml
of plasma.
Intraperitoneal glucose tolerance tests
10-week-old LDLR2/2 mice were fed a Western diet for
16 weeks. After an overnight fast, a single bolus of glucose (2 mg/g
body weight) was given intraperitoneally. Blood glucose levels were
determined by commercially available glucometer using tail vein
blood at 0, 15, 30, 60, 120 min.
Assessment of atherosclerosis by en face analyses
The aorta was dissected from the heart to the iliac bifurcation,
cleaned of any surrounding tissue, opened longitudinally, pinned
on black wax and fixed for 24 h in 10% buffered formalin. The
fixed aortas were imaged on a black background using a Canon
Digital Camera fitted with a 60 mm, f/2.8 Macro Lens. Total area
and the area occupied by the lesions in the aortic arch and total
aorta was determined using AxioVision Image Analysis software as
described earlier [17]. The person quantifying the area occupied
by lesions was blinded to the identity of the images.
Activation of macrophages
NF-kB driven luciferase expression. Thioglycollate elicited
peritoneal macrophages were plated in 24-well plates. Medium
was replaced after 4 h to remove non-adherent cells and cells were
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transduced with AdNF-kB-Luc (5 MOI) (Vector Labs, Burlin-
game, CA). After 24 h, cells were treated with 50 mM oleic acid
[18] for 24 h followed by LPS (50 pg/ml) for 4 h. Luciferase
activity was measured and normalized to cellular protein.
Secretion of cytokines and chemokines. Thioglycollate
elicited peritoneal macrophages were plated in 24-well plates.
Medium was replaced after 4 h to remove non-adherent cells and
cells were treated with LPS (50 pg/ml) 650 mM oleic acid for
24 h. Conditioned medium was used to determine the levels of
secreted IL-6 and MCP-1 levels by ELISA (eBioscience, San
Diego, CA).
Assessment of permeability of intestinal epithelial cell
monolayer
Caco-2 cells, obtained from the American Type Culture
Collection (ATCC, Rockville, MD, USA), were plated on
polycarbonate Transwells at 16105 cells/cm2 and grown in
DMEM (Life Technologies, Carlsbad, CA) containing fetal calf
serum (10% v/v), penicillin (100 U/ml) and streptomycin
(100 mg/ml) for 21 days at 37uC in 5% CO2 in air. Prior to
the start of the experiment the trans-epithelial electrical
resistance (TEER) of the Caco-2 cultures was measured with
an EVOM (World Precision Instruments, USA) to confirm their
fully differentiated state. TEER is a measure of tight junction
integrity and indicator of differentiation. Cultures displaying a
TEER greater than 700 V cm2 were considered suitable for the
study. Cells were pre-treated with 5 mM curcumin (in DMSO)
for 48 h before stimulating with LPS (1 mg/ml) in serum free
medium for 24 h.
Translocation of mannitol. After 24 hours, 1 ml [14C]
Mannitol (0.556105 dpm; 0.49 mmole) (Perkin Elmer, Akron,
OH) in HBSS was added to the apical side. Medium (50 ml, in
duplicate) was collected from the basolateral side at 0.5, 1, 2 and
4 hours to measure paracellular permeability.
Translocation of FITC Dextran. After 24 h, 1mg/ml
solution of FITC-Dextran in HBBS was added to the apical
chamber and medium (50 ml, in duplicate) was collected from the
basolateral side at 0.5, 1, 2 and 4 hours.
Expression of tight junction proteins
The detergent insoluble fraction corresponding to the actin
cytoskeleton-associated proteins was prepared as follows: Follow-
ing indicated treatments, Caco-2 cell monolayers were washed
with ice-cold HBSS and exposed for 10 minutes on ice to
500 mL of lysis buffer (1%Triton X-100, 5 mM EGTA in
50 mM Tris-HCl buffer pH 7.4 containing protease and
phosphatase inhibitor cocktail). Cell lysates were centrifuged at
14,000 g for 5 min at 4uC to sediment the high-density actin-rich
fraction. Proteins were separated on 4–20% gradient SDS-PAGE
(BioRad, Hercules, CA) transferred to PVDF membrane
(Millipore, Billereca MA) and used to determine the protein
levels of ZO-1 and Claudin-1 using specific antibodies (Santa
Cruz, Dallas TX) and normalized to b-actin.
Statistical analyses
Comparison between untreated and treated groups was
performed using Student’s t-test and P,0.05 was considered
significant. One way ANOVA with Bonferroni post-hoc correction
was used for multiple comparisons and details are included in
Figure legends.
Results
Western diet-induced release of endotoxin (LPS) due to
enhanced intestinal permeability was attenuated by oral
non-absorbable antibiotics or curcumin supplementation
A significant increase in plasma LPS levels (EU/ml) was
induced by Western diet (0.8260.77 vs 3.3261.79) and this
increase was attenuated in experimental groups receiving either
non-absorbable antibiotics (1.9060.91) or curcumin (1.5160.39)
(Figure 1A). LPS is continuously generated in the lumen of the
intestine by the gut bacteria and an intact intestinal barrier
prevents the release of even trace yet pathological amounts of
LPS into the circulation. Translocation of FITC-dextran 4kDa
to plasma compartment was monitored as an additional
parameter to directly assess improvement in intestinal barrier
function by antibiotics or curcumin. The appearance of orally
administered FITC dextran (ng FITC/ml plasma) was signifi-
cantly reduced by supplementation with non-absorbable antibi-
otics (2.1760.53 vs 1.5360.49) or curcumin (2.1160.32 vs
1.1360.15) further establishing an improvement in intestinal
barrier function by these two interventions (Figure 1B). In
addition to intestinal barrier function which restricts the release
of LPS that is continuously produced in the intestinal lumen,
intestinal alkaline phosphatase (IAP) associated with the brush
border detoxifies LPS by dephosphorylation of the Lipid A
moiety (the primary source of the endotoxic effects) and is
considered as an important gut mucosal defense factor.
Increased translocation of bacteria/bacterial products is ob-
served in IAP2/2 mice along with increased obesity [19]
emphasizing the role of IAP not only in maintaining the
intestinal barrier function but also in metabolic diseases.
Western diet feeding significantly reduced IAP activity
(,Q75%) and this decrease was attenuated by supplementation
with antibiotics (,Q25%) (Figure 1C). Notably, curcumin
supplementation significantly increased IAP activity compared
to chow diet fed control mice (,2 fold increase). These data
suggest that oral supplementation with antibiotics or curcumin
significantly improve intestinal barrier function and attenuate
the release of LPS into the circulation.
Table 1. Body weights, plasma cholesterol and triglyceride levels.
Treatment Body weight (g) Total Cholesterol (mg/dl) Total Triglyceride (mg/dl)
No Antibiotics 24.5865.37 1570.086531.81 267.50635.32
With Antibiotics 28.6866.20 1224.696381.08 378.29638.26
No Curcumin 26.2561.86 1511.296308.6 209.43652.4
With Curcumin 23.7264.04 1062.46313.7 153.3640.4
Prior to necropsy, mice were weighed and fasting plasma was collected. Total cholesterol and triglyceride levels were determined and shown as Mean 6 SD, n = 6–10.
doi:10.1371/journal.pone.0108577.t001
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Low dose LPS activates NF-kB and increases secretion of
pro-inflammatory cytokines/chemokines from
macrophages
While effects of high doses of LPS, as seen in sepsis, on
macrophage activation and subsequent production of pro-
inflammatory cytokines are well established, consequences of
low doses of LPS on macrophage activation and subsequent
signaling is only beginning to be evaluated. Under hyperlipid-
emic/hypercholesterolemic conditions that prevail following
consumption of Western diets, increased plasma lipids, especially
free fatty acids, can further contribute to macrophage activation
in cooperation with circulating LPS. To determine the contri-
bution of such a mechanism in macrophage activation, we
examined activation of pro-inflammatory transcription factor NF-
kB in mouse peritoneal macrophages. Low dose LPS (50 pg/ml)
significantly increased NF-kB-driven luciferase activity. Although
exposure to oleic acid (major fatty acid in Western diet) also
significantly increased NF-kB activation, the increase in luciferase
expression in the presence of LPS along with oleic acid was
significantly higher than that seen with LPS or oleic acid alone
suggestive of synergism (Figure 2A). These data suggest that in
the presence of Western diet derived oleic acid, trace amounts of
intestinally derived LPS can significantly activate pro-inflamma-
tory transcription factor NF-kB. Consequently, there was also a
significant increase in the secretion of pro-inflammatory cytokine
IL-6 (Figure 2B) and chemokine MCP-1 (Figure 2C) from
macrophages exposed to LPS in the presence of oleic acid.
Thus, Western diet feeding not only disrupts the intestinal barrier
function releasing gut bacteria derived LPS into circulation that
activates macrophages, but increased levels of circulating lipids
under these conditions further exacerbate macrophage activation
releasing pro-inflammatory chemokine/cytokines that can con-
tribute to macrophage infiltration into tissues resulting in chronic
inflammation and associated diseases.
Oral supplementation with non-absorbable antibiotics or
curcumin attenuates Western diet induced glucose
intolerance and atherosclerosis
Consumption of Western type diets is associated with the
development of glucose intolerance and/or heart disease. In
order to examine the potential effects of antibiotics or curcumin
supplementation on the development of these Western diet-
induced metabolic diseases, intra-peritoneal glucose tolerance
tests were performed after 16 weeks of feeding. Fasting glucose
levels were not significantly different between control and treated
mice. However, significant improvement in glucose tolerance was
observed by antibiotic (Figure 3A) or curcumin supplementation
(Figure 3B); the initial rise in blood glucose and levels at all-time
points were significantly lower in mice given antibiotics or
curcumin. Area under the curve, AUC, was calculated and a
significant decrease was observed in mice treated with antibiotics
(Figure 3C, 3940068000 vs 3020065800) or curcumin (Fig-
ure 3D, 36800612000 vs 2800067000).
Development of atherosclerosis was assessed by en face analyses
and representative images are shown in Figure 4A and 4B. A
dramatic reduction in the area occupied by atherosclerotic plaques
was observed in mice receiving non-absorbable antibiotics or
curcumin. Area occupied by the lesions was quantified and shown
Figure 1. Supplementation with non-absorbable antibiotics or
curcumin improves Western diet induced intestinal barrier
dysfunction. Ten week old LDLR2/2 mice were fed ad libitum High
Fat High Cholesterol containing Western type diet (TD 88137, WD) for
16 weeks. Experimental groups either received non-absorbable antibi-
otics (100 mg/L Neomycin and 10 mg/L Polymyxin B) in drinking water
or were gavaged daily with Curcumin (100 mg/kg in 0.5% carboxy-
methylcellulose). Panel A: Fasting plasma was collected at the time of
necropsy and circulating LPS levels (EU/ml) were determined. Data are
presented as Mean6 SEM, n = 6–9 per group. Panel B: Overnight fasted
mice were gavaged with FITC-dextran 4 kDa and plasma samples were
collected after 4 h. Appearance of FITC-dextran in plasma was
monitored and the data (Mean6SEM, n = 6–9, per group) are presented
as FITC concentration (ng/ml). Panel C: Intestinal Alkaline Phosphatase
activity was determined and Specific activity (nmoles PNP released/h/
mg protein) expressed as % chow-fed controls is shown (Mean 6 SEM,
n = 6–9 per group). P,0.0001 by One way ANOVA with Bonferroni post-
hoc correction; Dissimilar letters above the bars indicate significant
differences between groups (P,0.05).
doi:10.1371/journal.pone.0108577.g001
Figure 2. Increased macrophage activation by low dose LPS.
Panel A: Mouse peritoneal macrophages were transduced with AdNF-
kB-Luc and treated with LPS (50 pg/ml) or Oleic acid (50 mM) as
indicated. Luciferase activity was normalized to cellular protein and data
are presented as percent untreated Controls (Mean 6 SEM, n = 6). Panel
B and C: Conditioned medium was collected after incubation of mouse
peritoneal macrophages with LPS with or without oleic acid as
indicated and IL-6 and MCP-1 levels were determined by ELISA. Data
are expressed as percent of no addition control (Mean 6 SEM, n = 6).
P,0.0001 by One way ANOVA with Bonferroni post-hoc correction;
Dissimilar letters above the bars indicate significant differences
between groups (P,0.05).
doi:10.1371/journal.pone.0108577.g002
Intestinal Barrier Function and Metabolic Diseases
PLOS ONE | www.plosone.org 4 September 2014 | Volume 9 | Issue 9 | e108577
as percent of the total area. Supplementation with antibiotics
(Figure 4C) or curcumin (Figure 4D) significantly reduced the area
occupied by the lesions in the aortic arch (24.8261.52 vs
11.3461.26 and 32.0260.94 vs 25.2260.86, respectively) as well
as entire aorta (6.8260.5 vs 3.060.3 and 5.2060.5 vs 3.1460.3,
respectively). It is noteworthy that supplementation with antibiot-
ics or curcumin did not have any significant effect on plasma
cholesterol or triglyceride levels (Table 1) consistent with the
reported improvement in atherosclerosis with MyD88 and TLR4
deficiency in ApoE2/2 background without significant changes
in plasma lipids [20].
H&E stained aortic root sections were used to determine the
necrotic area within each plaque. Increased macrophage inflam-
mation is associated with necrosis of lesion associated macrophag-
es. As shown in Figures 4C and 4D, a significant decrease in
necrotic area was noted in antibiotic or curcumin treated mice
indicating reduced macrophage necrosis.
Improvement in intestinal barrier function is the
underlying mechanism of the observed effects of non-
absorbable antibiotics and curcumin
To further establish that intestine is the target organ for the
beneficial effects of non-absorbable antibiotics as well as curcumin,
LDLR2/2 mice on Western diet were given absorbable
antibiotics (Amoxicillin 100 mg/L) in drinking water. Amoxicillin
is rapidly absorbed (.1 h transit time in the intestine) and is likely
to have limited intestinal effects. Supplementation with amoxicillin
did not significantly affect Western-diet induced increase in plasma
LPS levels (Figure 5A) demonstrating a negligible effect on
intestinal barrier function. Furthermore, no change in IAP activity
was noted with amoxicillin supplementation (Figure 5B) confirm-
ing the intestine-localized effect of selective decontamination.
Consistently, supplementation with amoxicillin neither improved
Western diet-induced glucose intolerance (Figure 6A) nor had any
significant effect on atherosclerotic lesion development (Figur-
e 6BD and 6C). These data are consistent with limited effects
observed in clinical trials evaluating the use of antibiotics (e.g.,
Azithrimycin) in reducing the risk for heart disease [21] and also
provide additional support for the role of intestinal barrier
function in the development of chronic inflammatory diseases.
Curcumin improves intestinal barrier function
Currently no specific therapeutic strategies are available to
directly restore intestinal barrier function. Use of probiotics is
proposed, however, limited ability to be administered along with
other pharmaceuticals has been the major hurdle. Data presented
above identifies curcumin as an eco-biological phytochemical that
significantly restores Western diet-induced dysfunction of intestinal
barrier function. To further examine the direct effects of curcumin
on intestinal epithelial cells, Transwell-grown monolayers of
intestinal epithelial Caco-2 cells were exposed to LPS (to disrupt
barrier function) with or without pre-treatment with curcumin and
permeability of the monolayers determined by monitoring the
translocation of [3H]-mannitol or FITC dextran 4 KDa from the
apical to the basal side. Time dependent increase in the
translocation of [3H]-mannitol (Figure 7A) and FITC dextran
(Figure 7B) was induced following exposure to LPS. Although
curcumin did not have any effect on the basal or unstimulated
translocation, it significantly reduced LPS-induced translocation of
[3H]-mannitol as well as FITC dextran. These data establish the
direct effects of curcumin in preventing LPS-induced disruption of
intestinal epithelial cell barrier permeability.
Intestinal epithelium maintains its selective barrier function
through the formation of network of tight junction proteins such as
claudins and ZO-1. These proteins interact intracellularly with
adaptor proteins that link to the actin cytoskeleton [22] and
maintenance of intestinal barrier function is dependent on the
expression of tight junction protein associated with cytoskeletal
protein fraction or the detergent insoluble protein fraction [23].
When Caco-2 cells were exposed to LPS, there was 26% and 17%
decrease in detergent insoluble actin-associated ZO-1 (P= 0.01)
and claudin 1 expression (P= 0.05) respectively. This LPS-induced
reduction in expression was prevented in the presence of curcumin
(Figure 8A and 8B); curcumin alone in the absence of LPS had no
effect on ZO-1 or claudin 1 expression. Taken together with effects
of curcumin in reducing the translocation of [3H]-mannitol and
FITC in LPS-treated Caco-2 cells as well as attenuation of LPS
release in vivo, these data provide strong evidence that curcumin
can beneficially affect intestinal barrier function.
Discussion
The findings reported in this study not only demonstrate
Western diet-induced changes in intestinal barrier function
(reduction in IAP and tight junction proteins resulting in increased
permeability) leading to increased endotoxemia, macrophage
activation and subsequent development of glucose intolerance
and atherosclerosis but also establish that improvement of this
barrier function can significantly attenuate this pathological
sequelae (Figure 9). While selective gut decontamination by the
use of non-absorbable antibiotics provides the ‘‘proof of concept’’
that reduction in total intestinal bacterial content could be
beneficial in preventing Western diet-induced metabolic diseases,
the significant reduction in glucose intolerance as well as
Figure 3. Western diet-induced Glucose intolerance is attenu-
ated in mice receiving non-absorbable antibiotics or curcumin.
Ten week old LDLR2/2 mice were fed ad libitum High Fat High
Cholesterol containing Western type diet (TD 88137) for 16 weeks with
or without supplementation with non-absorbable antibiotics (Panels A
and C) or curcumin (Panels B and D). Panels A and B: Intraperitoneal
glucose tolerance tests were performed as described under Methods.
Blood glucose levels at indicated times are shown (Mean 6 SEM, n = 6).
Panels C and D: Area under the curve was calculated using GraphPad
Prism and data are presented as Mean 6 SEM, n = 6. *P,0.05. One way
ANOVA with Bonferroni post-hoc correction was also performed using
Western diet fed mice as controls (P,0.018) but no significant
difference (P.0.05) was observed between groups supplemented with
either antibiotics or curcumin indicative of similar effects of these two
treatments.
doi:10.1371/journal.pone.0108577.g003
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atherosclerosis by oral curcumin demonstrates the importance of
targeted improvement in intestinal barrier function as a potential
therapeutic strategy. This represents a change in the existing
paradigm and places the focus on improving intestinal barrier
function rather than direct modulation of gut bacteria itself.
Intestinal barrier is a multi-layer defense system [24] consisting
of lumen as the first line of defense where enzymatic degradation
of bacteria and antigens occurs and the commensal bacteria
prevent colonization of pathogens. The mucus layer prevents the
adherence of bacteria to the epithelial cells and reduces direct
bacterial-epithelial interactions. Tight junctions between the
epithelial cells restrict para-cellular transport of luminal contents.
Intestinal Alkaline Phosphatase (IAP) is part of the luminal first
line of defense and catalyzes the removal of one of the two
phosphate groups from the toxic lipid A moiety of LPS producing
monophosphoryl-LPS that still binds to TLR4 but predominantly
acts as an TLR4 antagonist [25]. We observed attenuation of
western-diet induced decrease in IAP activity by non-absorbable
antibiotics and an increase by curcumin. Tuin et al have reported
a decrease in IAP in patients with inflammatory bowel disease [26]
and heat stable, chimeric human alkaline phosphatase is currently
being evaluated as a protein therapeutic for gut dysbioses,
inflammatory bowel disease and acute kidney injury [27].
Restoration of Western diet-induced decrease in IAP activity by
selective gut decontamination as well as with curcumin supple-
mentation shown here strongly suggests a potential therapeutic use
of this strategy for multiple diseases. In this regard, it is noteworthy
that we have earlier demonstrated significant improvement in
chronic kidney disease by curcumin supplementation [28,29]. The
two interventions examined in this study also decreased para-
cellular transport and prevented western diet-induced reduction in
the expression of tight junction proteins (ZO-1 and Claudin-1).
Taken together, these data provide direct evidence for improve-
ment in the intestinal barrier function by these two interventions at
multiple levels namely luminal detoxification of LPS by IAP and
Figure 4. Supplementation with non-absorbable antibiotics or curcumin attenuates western diet induced atherosclerosis. Ten week
old LDLR2/2 mice were fed ad libitum High Fat High Cholesterol containing Western type diet (TD 88137) for 16 weeks with or without
supplementation with non-absorbable antibiotics (Panels A and C) or curcumin (Panels B and D). Panels A and B: Aortas were isolated at the time of
necropsy, cleaned of any adventitious tissue and imaged on a black background for en face analyses. Representative images are shown. Panel C and
D: Area occupied by atherosclerotic lesions in the total aorta or aortic arch and necrotic area in aortic root lesions was quantified and shown as %
Area (Mean 6 SEM, n = 9–11 per group). *P,0.05. One way ANOVA with Bonferroni post-hoc correction was also performed using Western diet fed
mice as controls (P,0.0001 for total and arch lesion area and P=0.0013 for necrotic area) but no significant difference (P.0.05) was observed
between groups supplemented with either antibiotics or curcumin indicative of similar effects of these two treatments.
doi:10.1371/journal.pone.0108577.g004
Figure 5. Effect of absorbable antibiotic Amoxicillin on
Western diet induced changes in intestinal barrier function.
Ten week old LDLR2/2 mice were fed ad libitum High Fat High
Cholesterol containing Western type diet (TD 88137) for 16 weeks with
or without supplementation with amoxicillin in drinking water. Panel A:
At the time of necropsy, fasting plasma was collected and LPS levels
were determined. Data are presented as Mean 6 SD, n= 6. Panel B:
Intestinal Alkaline Phosphatase activity was determined and Specific
activity (nmoles PNP released/h/mg protein) expressed as % chow-fed
controls is shown (Mean 6 SEM, n = 6).
doi:10.1371/journal.pone.0108577.g005
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paracellular transport of LPS by modulating expression of tight
junction proteins.
Low grade chronic inflammation is central to the development
of obesity and Western diet-induced metabolic diseases and trace,
yet pathological, amounts of intestine-derived LPS released into
the circulation accompanies many of these conditions [30].
Molecular mechanisms underlying the effects of such low grade
endotoxemia are not completely understood. Maitra et al have
recently described alternate signaling and activation of macro-
phages in vitro by exposure to low doses of LPS [31]. While
exposure to high doses of LPS prevents response to later
stimulation due to LPS-induced internalization of surface TLR4
(endotoxin tolerance), exposure to low doses of LPS exaggerates
the response to subsequent exposure to TLR4 ligands (priming)
[32], underscoring the importance to low grade endotoxemia in
exacerbation of macrophage inflammatory responses. Circulating
free fatty acids represent additional TLR4 ligands during
dyslipidemia caused by the consumption of Western type diet
Figure 6. Effect of absorbable antibiotic Amoxicillin on Western diet induced development of glucose intolerance and
atherosclerosis. Ten week old LDLR2/2 mice were fed ad libitum High Fat High Cholesterol containing Western type diet (TD 88137) for 16 weeks
with or without supplementation with amoxicillin in drinking water. Panel A: Intraperitoneal glucose tolerance tests were performed as described
under Methods. Blood glucose levels at indicated times are shown (Mean6 SEM, n = 6). Panel B: Aortas were isolated at the time of necropsy, cleaned
of any adventitious tissue and imaged on a black background for en face analyses. Representative images are shown. Panel C: Area occupied by
atherosclerotic lesions in the total aorta or aortic arch was quantified and shown as % Area (Mean 6 SEM, n = 6).
doi:10.1371/journal.pone.0108577.g006
Figure 7. Curcumin attenuates LPS-induced increase in intes-
tinal epithelia cell permeability. Panel A: Fully differentiated Caco-2
cell monolayers in Transwell inserts were treated with LPS or curcumin
and transport of [3H]-mannitol (expressed as dpm, Mean 6 SEM, n= 6)
to the bottom chamber was monitored at indicated time points. Panel
B: Improvement of LPS induced intestinal epithelial cell permeability by
curcumin was also assessed by monitoring the transport of FITC dextran
4 kDa across Caco-2 cell monolayer. Appearance of FITC dextran in the
bottom chamber at indicted time points was determined and expressed
as mg/ml. *P,0.05 compared to +LPS.
doi:10.1371/journal.pone.0108577.g007
Figure 8. Protection from LPS induced intestinal epithelia cell
dysfunction by Curcumin. Caco-2 cell monolayers were treated with
LPS or curcumin as indicated and detergent insoluble fractions were
analyzed by Western Blot analyses. Expression levels of ZO-1 (Panel A)
or Claudin-1 (Panel B) were normalized to b-actin and presented as
percent of untreated controls. *P,0.05 compared to untreated controls.
doi:10.1371/journal.pone.0108577.g008
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and the data presented here demonstrates more than additive
effect of LPS and oleic acid on macrophage activation suggesting
that this diet contributes to low grade chronic inflammation by
first increasing the release of gut-derived LPS into circulation that
can prime the macrophages and secondly by increasing the
circulating free fatty acids that can further exacerbate this
inflammatory response. While infiltration of activated macrophag-
es into adipose tissue and resulting adipose tissue inflammation
underlie the development of insulin resistance and diabetes,
macrophage infiltration into artery wall and conversion to lipid
laden foam cells leads to the development of atherosclerosis
(Figure 9).
Curcumin, a polyphenolic natural compound and a principal
ingredient of Asian spice Turmeric is reported to possess anti-
inflammatory and anti-oxidant properties. However, the mech-
anisms underlying its observed effects have not been completely
understood. Dietary curcumin is poorly absorbed and undergoes
glucuronidation and excretion limiting its release into the
circulation. Consequently, significant efforts are currently being
directed to the development of novel methods for systemic or
targeted delivery of curcumin [33]. The data presented here
demonstrate for the first time that curcumin exerts potent effects
in reducing metabolic diseases such as diabetes and atheroscle-
rosis by modulating the intestinal barrier function, precluding
the need for effective absorption and systemic bioavailability.
Curcumin-mediated reduction in ox-LDL uptake by THP-1
cells in vitro and reduction in inflammatory cytokines in vivo
were thought to be the mechanisms underlying the observed
decrease in atherosclerosis [34]. Based on the observed
reduction in monocyte adhesion to curcumin treated endothelial
monolayers in vitro, Coban et al speculated that reduced
macrophage infiltration is likely the underlying mechanism for
the observed reduction in atherosclerosis by dietary curcumin
[35]. In a recent Phase II trial to evaluate the efficacy of oral
curcumin for pancreatic cancer, despite an oral dose of 8 g/day,
negligible amounts of free curcumin was detected in the plasma
and total curcumin levels (free + glucuronated/sulfated) were in
the range of ng/ml, significantly lower than the dose used in
most in vitro studies [36]. While low bioavailability may have
thus far precluded the development of curcumin as a potent
anti-inflammatory or anti-cancer agent, the current study
provides a novel mechanism of action of curcumin. It is
noteworthy that a recent pilot clinical study for cancer
chemoprevention has demonstrated the safety of oral curcumin
for long term use [37] paving the way for future studies to
evaluate the efficacy of this phytochemical for attenuation of
Western diet-induced metabolic diseases.
In conclusion, the data presented here provide direct evidence
for the role of Western diet-induced disruption of intestinal barrier
function in the development of metabolic diseases such as diabetes
and atherosclerosis. Furthermore, these studies also identify
curcumin as an agent effective in restoring the intestinal barrier
function by modulating multiple components of this barrier
including IAP and paracellular permeability. Future studies will
examine the effects of curcumin on other components of the
intestinal barrier to further advance our current understanding
and to develop curcumin as a dietary supplement to attenuate
multiple inflammation-linked diseases.
Figure 9. Proposed model for attenuation of Western diet induced changes in intestinal barrier dysfunction and subsequent
development of glucose intolerance and atherosclerosis by non-absorbable antibiotics or curcumin. Under normal physiological
conditions, intestinal barrier restricts the release of luminal LPS from gut bacteria into circulation. Intestinal alkaline phosphatase (IAP) is one of the
major components of this ‘‘barrier’’ and it detoxifies LPS by dephosphorylation of the Lipid A moiety. Consumption of Western diet decreases IAP
(Figure 1B) thereby increasing the effects of luminal LPS on intestinal epithelial cells and increasing intestinal permeability (Figure 1C). Luminal LPS-
induced decrease in the expression of tight junction proteins ZO-1 and Claudin -1 (Figure 3G) increases the paracellular transport of LPS into
circulation (Figure 1A). Trace yet pathological doses of LPS along with Western diet-induced increase in circulating lipids (e.g., fatty acids) enhance
macrophage activation and induce NF-kB-driven gene expression (Figure 3A) resulting in increased secretion of pro-inflammatory cytokines and
chemokines (Figure 3C and D). Increased infiltration of activated macrophages into adipose tissue or artery wall leads to the development of glucose
intolerance and atherosclerosis. Administration of non-absorbable antibiotics or curcumin prevents Western diet-induced disruption of intestinal
barrier function and thereby attenuates these sequential events resulting in attenuation of Western diet-induced glucose intolerance and
atherosclerosis (Figure 2).
doi:10.1371/journal.pone.0108577.g009
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